CTSB and Hepatic fibrosis: Taken together, these results show that cathepsin B was significantly superior to APRI (AUROC = 0.71 ± 0.05) and FIB4 (AUROC = 0.67 ± 0.06) in assessing significant liver fibrosis (control versus F2–4) in CHC patients.